Intuniv generic
Intuniv is an ADHD treatment drug owned by Takeda Pharms Usa. The drug's active ingredient is guanfacine hydrochloride. It was first authorized for market use on the 2nd of September, 2009. It is available in tablet and extended release; oral dosage forms. Intuniv is protected by a total of 2 patents, with all 2 of these patents now expired.
When will Intuniv generic be available?
The generics of Intuniv are set to be released after the 4th of January, 2023. This date marks the expiration of the last active patent, US6811794*PED. Even though the core patent of the drug expired on the 4th of July, 2022, the Controlled-Release version (US6811794*PED) holds its rule till 2023 due to Para IV filing.
Intuniv uses
Intuniv is used to manage and treat symptoms of attention-deficit hyperactivity disorder (ADHD). Its active ingredient, guanfacine hydrochloride, works by stimulating the receptors in the brain that help reduce the symptoms of ADHD.
Intuniv patent expiration
Intuniv's last remaining patent (US6811794*PED) is set to expire on the 4th of January, 2023, which will therefore allow the availability of Intuniv generics on the market. Below are the details of the patent: